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ABSTRACT
Background: In dogs with bacterial cystitis that is resistant to multiple antibiotics, resulting from repeated infections and 
antimicrobial administration, especially if the dog has impaired renal function and the induction of systemic side effects 
by intravenous or oral administration is a concern, intravesical instillation of antibiotics might represent an alternative 
treatment option. In human and veterinary medicine, a number of studies showed intravesical instillation of antibiotics is 
effective for the therapy multidrug-resistant bacterial urinary tract infection (UTI). This report firstly illustrates successful 
intravesical meropenem treatment of a UTI caused by multidrug-resistant Escherichia coli with no systemic side effects 
in dog with chronic kidney disease (CKD).
Case: A 15-year-old spayed female Maltese was presented with recurrent bacterial cystitis. The risk factors for the recur-
rent UTI were spinal cord injury and CKD which had been managed for 1 year. Ultrasound-guided cystocentesis was 
performed to obtain a urine sample for urinalysis, bacteriologic culture, and antibiotic susceptibility testing. Bacterial 
cystitis caused by multidrug-resistant Escherichia coli was diagnosed on the basis of bacterial culture, and antimicrobial 
susceptibility testing. Because the dog had CKD, reducing the clearance of meropenem, intravesical instillation of anti-
biotics was initiated. The intravesical instillation process consisted of the emptying of the urinary bladder, infusion of a 
diluted meropenem solution (8.5 mg/kg diluted in 20 mL of saline solution) into the bladder through a urethral catheter, 
and retention of the meropenem solution in the bladder for 1 h, and its removal. The procedure was repeated every 8 h. On 
day 8 of the intravesical instillation therapy, bactereologic culture yielded a growth of E. coli (50,000 CFUs/mL), which 
was less than previously obtained. the concentration of the meropenem solution being administered was increased to 17 
mg/kg diluted in 20 mL of saline solution, to improve the effectiveness of the therapy. After 21 days of the intravesical 
meropenem instillation, the bacterial cystitis was resolved. One year after completion of the treatment, the dog is still alive 
without any recurrence of bacterial cystitis. 
Discussion: Because resistant uropathogens can cause zoonotic infections, effective therapy is important with increasing 
incidence not only for patients, but also for public health. Intravesical instillation of antibiotics can be an effective treatment 
method for dogs with urinary tract infection in which oral antibiotics are likely to be ineffective and injectable antibio-
tics cannot be a treatment option. The antibiotics can be administered directly to the affected location, and systemic side 
effects can be minimized by the impermeabtility of the bladder wall via intravesical instillation procedure. Meropenem is 
likely to accumulate in dogs with impaired renal function, leading to systemic side effects and the aggravation of CKD in 
old dogs. This report describes the successful treatment of multidrug-resistant E. coli infection by intravesical instillation 
of meropenem without any side effects in dogs with CKD. Therefore, clinician should consider the use of intravesical 
instillation of antibiotics which predominately excreted in the urine for the control of urinary tract infection caused by 
multidrug-resistant bacteria in dogs showing reduced renal function.
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INTRODUCTION
Urinary tract infection (UTI) is a common di-
sease of humans [6] and dogs [4] that may occur when 
the normal defense mechanisms are compromised. UTI 
is predisposed to many factors, and develops secondary 
to interactions between the virulence of an organism 
and underlying anatomic, functional, immunological, 
or metabolic abnormalities or comorbidities in the 
host. In humans, infections, caused by various resis-
tant pathogens are associated with significantly higher 
morbidity, mortality, and treatment costs. In veterinary 
medicine, there is still a lack of relevant information, 
but multidrug-resistant infections are emerging as a 
significant issue. Antibiotic resistance of uropathogens 
complicates therapy in dogs and is a public health 
concern because these pathogens may be zoonotic 
[4,8,10]. In human and veterinary medicine, a number 
of studies showed intravesical instillation of antibiotics 
is effective for the therapy multidrug-resistant bacterial 
UTI [3,10-12]. This report describes the case of a dog 
with UTI caused by multidrug-resistant Escherichia 
coli infection, which was successfully managed by 
intravesical instillation of meropenem for 21 days, 
without any side effects.
CASE 
A 15-year-old spayed female Maltese weighing 
3.32 kg was presented with recurrent bacterial cystitis. 
The dog had a history of paraplegia caused by vertebral 
fracture and spinal injury, and was unable to volun-
tarily empty its bladder. The dog had ureteral calculi 
and chronic kidney disease (CKD), which had been 
managed for 1 year. The complete blood count (CBC) 
was within normal limits. Abnormalities detected on 
serum biochemical analysis included increased activity 
of alkaline phosphatase (ALP) [212 IU/L; reference 
interval [RI], 29-97 IU/L], and slightly high blood 
urea nitrogen (BUN) [28.8 mg/dL; RI, 7-25 mg/dL]. 
Ultrasonography of the abdomen revealed an irregu-
larly thickened bladder wall, moderate irregularity in 
the margin of left kidney, and a severe reduction in 
renal corticomedullary definition. 
Ultrasound-guided cystocentesis was perfor-
med to obtain a urine sample for urinalysis. Bacteriolo-
gic culture of the urine yielded a growth of Escherichia 
coli (>100,000 CFUs/mL), which subsequent testing 
revealed was susceptible only to imipenem and me-
ropenem, and no growth of other bacteria. Urinalysis 
revealed bacteriuria but no bilirubin, glucose, ketone, 
or uribilinogen, and the urine sediment contained 100 
white blood cells (WBCs)/high power filed (hpf) and 
5 red blood cells (RBCs)/hpf. Therefore, bacterial 
cystitis caused by multidrug-resistant Escherichia.coli 
infection was diagnosed, and the dog was hospitalized.
Because meropenem is predominately excreted 
unchanged in the urine, it is likely to accumulate in 
dogs with impaired renal function, leading to systemic 
side effects and the aggravation of CKD. Therefore, 
intravesical instillation, instead of intravenous injection, 
of meropenem1 was initiated. The intravesical instilla-
tion process consisted of the emptying of the urinary 
bladder, infusion of a diluted meropenem solution (8.5 
mg/kg diluted in 20 mL of saline [0.9% NaCl] soluti-
on) into the bladder through a urethral catheter, and 
retention of the meropenem solution in the bladder for 
1 h, and its removal (Figure 1). The urethral catheter 
was changed every other day. No abnormalities in vital 
signs developed, and there was no hematuria, which 
can occur when the drug irritates the bladder wall and 
intravescial instillation was repeated every 8 h. On day 
8 of the intravesical instillation therapy, a urine sam-
ple was obtained via the urethral catheter for bacterial 
culture and urinalysis. Bactereologic culture yielded a 
growth of E. coli (50,000 CFUs/mL), which was less 
than previously obtained, and urinalysis revealed a urine 
sediment containing 3 WBCs /hpf and 5 RBCs /hpf. 
Consequently, the concentration of the mero-
penem solution being administered was increased to 17 
mg/kg diluted in 20 mL of saline solution, to improve 
the effectiveness of the therapy, which resulted in 
no detectable side effects. On day 15 of the therapy, 
a further urine sample was obtained via the urethral 
catheter. Bacteriologic culture yielded no growth of 
multidrug-resistant E. coli. On day 21, a further blood 
sample was obtained for CBC and serum biochemical 
analysis, and all of the parameters were within their 
respective RIs. Therefore, the intravesical instillation 
of meropenem was discontinued and the dog was 
discharged. Over the next one year, the dog continued 
to be routinely re-evaluated, and there has been no 
recurrence of bacterial cystitis until now. 
DISCUSSION
UTI caused by bacteria is common in humans 
and many domestic animals, and antimicrobial treatment 
is a risk factor for the development antimicrobial resis-
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tance. Because resistant uropathogens can cause zoonotic 
infections, effective therapy is important with increasing 
incidence not only for patients, but also for public health.
UTI caused by multidrug-resistant bacteria 
frequently occurs in dogs with spinal cord injury, 
which causes incomplete voiding of urine, such as the 
dog of this report, and it is challenging to manage this 
effectively. Because the dog described in the present 
report had a history of paraplegia caused by spinal cord 
injury, following vertebral fracture, which resulted in 
incomplete voiding of urine, UTI was a frequent pro-
blem, and its history of regular reinfection increased 
the risk of treatment failure on each occasion. 
Intravesical instillation of antibiotics can be 
an effective treatment method for dogs with UTIs in 
which oral antibiotics are likely to be ineffective and 
injectable antibiotics cannot be a treatment option. The 
drug is administered directly to the affected location, 
and systemic side effects can be minimized by the 
impermeabtility of the bladder wall. In addition, the 
adverse effects, such as nausea, diarrhea, and colonic 
superinfection associated with some oral agents pas-
sing through the gastrointestinal tract, can be avoided. 
In a previous study of instravescial instillation of gen-
tamicin sulfate in dogs [7], serum gentamicin sulfate 
levels were not detectable, and the serum creatinine 
Figure 1. A schematic diagram (created by Dr. Jongchul Yun) of the intravesical instillation of meropenem. Emptying of the urinary bladder (A & B). 
Infusion of a diluted meropenem solution into the bladder through a urethral catheter (C). Retention of the meropenem solution in the bladder for 1 h 
and its subsequent removal.
4
                                                                                                           J. Yun, T. Yun, Y. Koo, et al. 2022. Cystitis in a Bitch with Chronic Kidney Disease Caused by Multidrug-Resistant Escherichia coli. 
                                                                                                                  Acta Scientiae Veterinariae. 50(Suppl 1): 749.
concentration was not affected. These results indicate 
that intravesical instillation of antibiotics is associated 
with fewer systemic side effects.
Escherichia coli is one of the main participants 
in the dissemination of antimicrobial resistance [9], and 
in both dogs and cats, prior antibiotic administration 
and recurrent infection are the principal risk factors for 
the development of multidrug-resistant infections [2,5]. 
The multidrug-resistance Escherichia coli responsible 
for the UTI in this case was shown to be susceptible to 
imipenem and meropenem. Compared wih iminepem, 
meropenem is not a substrate for dehydropeptidase-I, a 
metabolizing enzyme present in renal proximal tubule 
cells and the brush border, making the concomitant ad-
ministration of a dehydropeptidase-I inhibitor, such as 
cilastatin, unnecessary. In addition, meropenem causes 
less nephrotoxicity and neurotoxicity than imipenem, 
but the clearance of meropenem from plasma is slower, 
and therefore the plasma meropenem concentration is 
maintained for longer, in patients with reduced renal 
function than in healthy people [1]. Because the dog 
described herein had CKD, its blood meropenem con-
centration was likely to remain undesirably high for a 
long period, which could result in systemic side effects, 
if the drug was administered by intravenous injection. 
Furthermore, because meropenem is eliminated largely 
without having been metabolized, in urine, the dog’s 
CKD was likely to be aggravated by the accumulation 
of meropenem. Incomplete treated bacterial cystitis 
may also negatively impact the renal parenchyma, 
therefore, the dog required more effective treatment 
of its cystitis. Of the limited treatment options, intra-
vesical instillation of meropenem was chosen because 
it should be associated with the fewest side effects and 
have the best therapeutic efficacy. 
A previous case report described the successful 
treatment of a dog with a UTI caused by Pseudomonas 
aeruginosa using intravesical instillation of amika-
cin for 27 days [11]. In this instance, the dose and 
frequency of antibiotics used were the same as that 
recommended for intravenous administration, because 
information regarding the most appropriate dose and 
frequency for intravesical instillation was not avai-
lable. The dog developed hematuria after 27 days of 
intravesical treatment that resolved within 7 days of the 
discontinuation of treatment. In the case reported here, 
intravesical instillation of meropenem was performed 
at the same dose as that recommended for intravenous 
administration (8.5 mg/kg) and repeated every 8 h until 
day 15, when the dose was increased to 17 mg/kg until 
day 21. Despite this increase in dose, the dog did not 
develop any side effects.
The limitations of drug administration by 
intravesical instillation are the time and labor requi-
red to perform transurethral catheterization for each 
administration, especially in female dogs, or for the 
maintenance of a sterile indwelling urethral catheter. 
In addition, if the bladder epithelium is inflamed, it 
is difficult to predict the circulating concentration 
of antibiotics that will result, which if high may be 
associated with adverse effects; therefore, continuous 
evaluation of the dog is required during therapy. This 
means that treatment is best undertaken when the dog 
is hospitalized, and the prolonged stay required may 
render it too expensive option for owners.
This case report illustrates successful intrave-
sical treatment of a UTI caused by multidrug-resistant 
Escherichia coli over 21 days, with no evidence of sys-
temic side effects. In bacterial cystitis that is resistant to 
multiple antibiotics, resulting from repeated infections 
and antimicrobial administration, especially if the dog 
has impaired renal function and the induction of syste-
mic side effects by intravenous or oral administration is 
a concern, intravesical instillation of antibiotics might 
represent a useful treatment option. However, there is 
a lack of published information regarding the optimal 
dose, frequency, and duration of intravesical treatment 
required for a positive outcome. Therefore, further in-
vestigation is needed to be established the most ensure 
effective intravesical protocol and to assess the efficacy 
of other intravesical protocols for the treatment of UTIs 
caused by multidrug-resistant bacteria.
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